BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26975711)

  • 1. SmgGDS as a Crucial Mediator of the Inhibitory Effects of Statins on Cardiac Hypertrophy and Fibrosis: Novel Mechanism of the Pleiotropic Effects of Statins.
    Kudo S; Satoh K; Nogi M; Suzuki K; Sunamura S; Omura J; Kikuchi N; Kurosawa R; Satoh T; Minami T; Ikeda S; Miyata S; Shimokawa H
    Hypertension; 2016 May; 67(5):878-89. PubMed ID: 26975711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation.
    Tanaka S; Fukumoto Y; Nochioka K; Minami T; Kudo S; Shiba N; Takai Y; Williams CL; Liao JK; Shimokawa H
    Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1591-600. PubMed ID: 23640485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins up-regulate SmgGDS through β1-integrin/Akt1 pathway in endothelial cells.
    Minami T; Satoh K; Nogi M; Kudo S; Miyata S; Tanaka S; Shimokawa H
    Cardiovasc Res; 2016 Jan; 109(1):151-61. PubMed ID: 26598509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
    Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
    Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors.
    Rashid M; Tawara S; Fukumoto Y; Seto M; Yano K; Shimokawa H
    Circ J; 2009 Feb; 73(2):361-70. PubMed ID: 19060417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury.
    Yagi S; Akaike M; Aihara K; Ishikawa K; Iwase T; Ikeda Y; Soeki T; Yoshida S; Sumitomo-Ueda Y; Matsumoto T; Sata M
    Hypertension; 2010 Apr; 55(4):918-23. PubMed ID: 20194307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small GTP-Binding Protein GDP Dissociation Stimulator Prevents Thoracic Aortic Aneurysm Formation and Rupture by Phenotypic Preservation of Aortic Smooth Muscle Cells.
    Nogi M; Satoh K; Sunamura S; Kikuchi N; Satoh T; Kurosawa R; Omura J; Elias-Al-Mamun M; Abdul Hai Siddique M; Numano K; Kudo S; Miyata S; Akiyama M; Kumagai K; Kawamoto S; Saiki Y; Shimokawa H
    Circulation; 2018 Nov; 138(21):2413-2433. PubMed ID: 29921611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CIKS (Act1 or TRAF3IP2) mediates Angiotensin-II-induced Interleukin-18 expression, and Nox2-dependent cardiomyocyte hypertrophy.
    Valente AJ; Clark RA; Siddesha JM; Siebenlist U; Chandrasekar B
    J Mol Cell Cardiol; 2012 Jul; 53(1):113-24. PubMed ID: 22575763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of HMG CoA reductase inhibition on small GTPases in the heart.
    Laufs U; Kilter H; Konkol C; Wassmann S; Böhm M; Nickenig G
    Cardiovasc Res; 2002 Mar; 53(4):911-20. PubMed ID: 11922901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy.
    Hingtgen SD; Tian X; Yang J; Dunlay SM; Peek AS; Wu Y; Sharma RV; Engelhardt JF; Davisson RL
    Physiol Genomics; 2006 Aug; 26(3):180-91. PubMed ID: 16670255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice.
    Xu Z; Okamoto H; Akino M; Onozuka H; Matsui Y; Tsutsui H
    J Cardiovasc Pharmacol; 2008 Jan; 51(1):62-70. PubMed ID: 18209570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy.
    Sun B; Huo R; Sheng Y; Li Y; Xie X; Chen C; Liu HB; Li N; Li CB; Guo WT; Zhu JX; Yang BF; Dong DL
    Hypertension; 2013 Feb; 61(2):352-60. PubMed ID: 23248151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of farnesyl pyrophosphate synthase attenuates angiotensin II-induced cardiac hypertrophy and fibrosis in vivo.
    Yang J; Zhu HH; Chen GP; Ye Y; Zhao CZ; Mou Y; Hu SJ
    Int J Biochem Cell Biol; 2013 Mar; 45(3):657-66. PubMed ID: 23277274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sildenafil Does Not Prevent Heart Hypertrophy and Fibrosis Induced by Cardiomyocyte Angiotensin II Type 1 Receptor Signaling.
    Straubinger J; Schöttle V; Bork N; Subramanian H; Dünnes S; Russwurm M; Gawaz M; Friebe A; Nemer M; Nikolaev VO; Lukowski R
    J Pharmacol Exp Ther; 2015 Sep; 354(3):406-16. PubMed ID: 26157043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of atorvastatin to inhibit hypoxia-induced myocardin expression.
    Chiu CZ; Wang BW; Shyu KG
    Eur J Clin Invest; 2012 May; 42(5):564-71. PubMed ID: 22129233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crucial Role of ROCK2-Mediated Phosphorylation and Upregulation of FHOD3 in the Pathogenesis of Angiotensin II-Induced Cardiac Hypertrophy.
    Zhou Q; Wei SS; Wang H; Wang Q; Li W; Li G; Hou JW; Chen XM; Chen J; Xu WP; Li YG; Wang YP
    Hypertension; 2017 Jun; 69(6):1070-1083. PubMed ID: 28438902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes.
    Godoy JC; Niesman IR; Busija AR; Kassan A; Schilling JM; Schwarz A; Alvarez EA; Dalton ND; Drummond JC; Roth DM; Kararigas G; Patel HH; Zemljic-Harpf AE
    FASEB J; 2019 Jan; 33(1):1209-1225. PubMed ID: 30169110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition.
    Yamanouchi D; Banno H; Nakayama M; Sugimoto M; Fujita H; Kobayashi M; Kuwano H; Komori K
    J Vasc Surg; 2005 Oct; 42(4):757-64. PubMed ID: 16242565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.
    Zhong J; Basu R; Guo D; Chow FL; Byrns S; Schuster M; Loibner H; Wang XH; Penninger JM; Kassiri Z; Oudit GY
    Circulation; 2010 Aug; 122(7):717-28, 18 p following 728. PubMed ID: 20679547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh.
    Choi EY; Chang W; Lim S; Song BW; Cha MJ; Kim HJ; Choi E; Jang Y; Chung N; Hwang KC
    Eur J Pharmacol; 2010 Feb; 627(1-3):56-62. PubMed ID: 19883640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.